Ozomet-VG2 Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby lowering basal and postprandial glucose levels. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, attenuating postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged drug release, maintaining stable plasma concentrations and improving patient compliance by reducing dosing frequency. Ozomet-VG2 is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy or dual therapy is insufficient to achieve glycemic targets. It should be used under medical supervision with regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis risk associated with Metformin. This combination therapy offers a comprehensive approach to glycemic control by targeting multiple pathophysiological defects in type 2 diabetes.